NASDAQ:BPMC Blueprint Medicines - BPMC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. $44.99 +0.70 (+1.58%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$44.32▼$45.7450-Day Range$37.97▼$49.0652-Week Range$37.82▼$79.40Volume470,742 shsAverage Volume573,923 shsMarket Capitalization$2.70 billionP/E RatioN/ADividend YieldN/APrice Target$72.68 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Blueprint Medicines MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside61.6% Upside$72.68 Price TargetShort InterestBearish8.77% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 8 Articles This WeekInsider TradingSelling Shares$1.27 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($10.00) to ($7.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.11 out of 5 starsMedical Sector488th out of 1,004 stocksPharmaceutical Preparations Industry227th out of 489 stocks 4.3 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 8 buy ratings, 6 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $72.68, Blueprint Medicines has a forecasted upside of 61.6% from its current price of $44.99.Amount of Analyst CoverageBlueprint Medicines has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.77% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Blueprint Medicines has recently decreased by 4.88%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 2.0 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Blueprint Medicines this week, compared to 3 articles on an average week.Search InterestOnly 6 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of -81% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,265,091.00 in company stock.Percentage Held by InsidersOnly 3.42% of the stock of Blueprint Medicines is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($10.00) to ($7.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -4.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 5.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Blueprint Medicines (NASDAQ:BPMC) StockBlueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.Read More Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Stock News HeadlinesMarch 30, 2023 | markets.businessinsider.com16 Analysts Have This to Say About Blueprint MedicinesMarch 30, 2023 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Blueprint Medicines (BPMC)April 1, 2023 | Vantage Point (Ad)What To Do With Your Trades TodayThere’s a tool that scans and picks the best stocks… and could give you all the consistency you need in your trading… No matter what happens in the market. Revealed Here: A.I. Predicted Stock Forecasts March 29, 2023 | seekingalpha.comExploring Blueprint's 'Blockbuster Opportunity' In Indolent Systemic MastocytosisMarch 28, 2023 | finance.yahoo.comBlueprint Medicines Announces Lift of Partial Clinical Hold on Phase 1/2 VELA Trial of BLU-222March 24, 2023 | finance.yahoo.comWhy Is Editas (EDIT) Down 21% Since Last Earnings Report?March 21, 2023 | americanbankingnews.comBlueprint Medicines (NASDAQ:BPMC) Price Target Increased to $84.00 by Analysts at Stifel NicolausFebruary 27, 2023 | finance.yahoo.comBlueprint Medicines Highlights Detailed Data From Lead Product In Blood Cancer PatientsApril 1, 2023 | Investorplace Media (Ad)5 Stocks to Buy ImmediatelyAmerica’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. February 23, 2023 | msn.comBlueprint Medicines, Roche end partnership for cancer medicineFebruary 23, 2023 | finance.yahoo.comBlueprint Medicines to Regain Global Rights to GAVRETO® (pralsetinib) from RocheFebruary 20, 2023 | finance.yahoo.comBlueprint Medicines Corporation (NASDAQ:BPMC) Q4 2022 Earnings Call TranscriptFebruary 18, 2023 | seekingalpha.comBlueprint Medicines Corporation (BPMC) Q4 2022 Earnings Call TranscriptFebruary 17, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on Blueprint Medicines (BPMC)February 17, 2023 | finance.yahoo.comBlueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock UpFebruary 16, 2023 | finance.yahoo.comBiotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer UpdatesFebruary 16, 2023 | finanznachrichten.deBlueprint Medicines Corporation: Blueprint Medicines Reports Fourth Quarter and Full Year 2022 ResultsFebruary 16, 2023 | finance.yahoo.comBlueprint Medicines Reports Fourth Quarter and Full Year 2022 ResultsFebruary 15, 2023 | msn.comEarnings Preview For Blueprint MedicinesFebruary 10, 2023 | finanznachrichten.deBlueprint Medicines Corporation: Blueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222February 10, 2023 | marketwatch.comBlueprint Medicines BLU-222 Study on FDA Partial Hold >BPMCFebruary 10, 2023 | reuters.comU.S. FDA puts partial hold on Blueprint Medicines cancer drug trialFebruary 10, 2023 | markets.businessinsider.comBlueprint Medicines Says FDA Places Partial Clinical Hold On Phase 1/2 VELA Trial Of BLU-222February 10, 2023 | finance.yahoo.comIs Blueprint Medicines Corporation (NASDAQ:BPMC) Expensive For A Reason? A Look At Its Intrinsic ValueFebruary 10, 2023 | finance.yahoo.comBlueprint Medicines Announces Partial Clinical Hold for Phase 1/2 VELA Trial of BLU-222February 9, 2023 | markets.businessinsider.comBerenberg Bank Keeps Their Buy Rating on Blueprint Medicines (BPMC)February 9, 2023 | finance.yahoo.comBlueprint Medicines to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address BPMC Company Calendar Last Earnings2/16/2023Today3/31/2023Next Earnings (Estimated)5/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees495Year Founded2011Price Target and Rating Average Stock Price Forecast$72.68 High Stock Price Forecast$114.00 Low Stock Price Forecast$38.00 Forecasted Upside/Downside+61.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($9.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-557,520,000.00 Net Margins-273.24% Pretax Margin-270.68% Return on Equity-80.09% Return on Assets-43.35% Debt Debt-to-Equity Ratio0.24 Current Ratio5.71 Quick Ratio5.55 Sales & Book Value Annual Sales$204.04 million Price / Sales13.23 Cash FlowN/A Price / Cash FlowN/A Book Value$8.60 per share Price / Book5.23Miscellaneous Outstanding Shares59,980,000Free Float57,933,000Market Cap$2.70 billion OptionableOptionable Beta0.70 Social Links Key ExecutivesKathryn HavilandPresident, Chief Executive Officer & DirectorChristina RossiChief Operating OfficerMichael LandsittelChief Financial OfficerChristopher K. MurraySenior Vice President-Technical OperationsBecker HewesChief Medical OfficerKey CompetitorsArrowhead PharmaceuticalsNASDAQ:ARWRAxsome TherapeuticsNASDAQ:AXSMRevance TherapeuticsNASDAQ:RVNCUltragenyx PharmaceuticalNASDAQ:RAREMyovant SciencesNYSE:MYOVView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 2,558 shares on 3/27/2023Ownership: 0.008%ETF Managers Group LLCBought 4,616 shares on 3/23/2023Ownership: 0.008%Jeffrey W AlbersSold 9,793 sharesTotal: $447,246.31 ($45.67/share)Kate HavilandSold 6,640 sharesTotal: $303,381.60 ($45.69/share)Christina RossiSold 3,059 sharesTotal: $139,704.53 ($45.67/share)View All Insider TransactionsView All Institutional Transactions BPMC Stock - Frequently Asked Questions Should I buy or sell Blueprint Medicines stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last twelve months. There are currently 1 sell rating, 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares. View BPMC analyst ratings or view top-rated stocks. What is Blueprint Medicines' stock price forecast for 2023? 16 equities research analysts have issued 12 month price targets for Blueprint Medicines' stock. Their BPMC share price forecasts range from $38.00 to $114.00. On average, they anticipate the company's stock price to reach $72.68 in the next year. This suggests a possible upside of 61.6% from the stock's current price. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. How have BPMC shares performed in 2023? Blueprint Medicines' stock was trading at $43.81 at the beginning of the year. Since then, BPMC stock has increased by 2.7% and is now trading at $44.99. View the best growth stocks for 2023 here. When is Blueprint Medicines' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 2nd 2023. View our BPMC earnings forecast. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) posted its earnings results on Thursday, February, 16th. The biotechnology company reported ($2.65) EPS for the quarter, beating analysts' consensus estimates of ($2.73) by $0.08. The biotechnology company had revenue of $38.78 million for the quarter, compared to the consensus estimate of $33.52 million. Blueprint Medicines had a negative trailing twelve-month return on equity of 80.09% and a negative net margin of 273.24%. The firm's quarterly revenue was down 63.8% compared to the same quarter last year. During the same period last year, the business posted ($0.99) EPS. What ETFs hold Blueprint Medicines' stock? ETFs with the largest weight of Blueprint Medicines (NASDAQ:BPMC) stock in their portfolio include iShares Genomics Immunology and Healthcare ETF (IDNA), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Products ETF (BBP), First Trust Nasdaq Pharmaceuticals ETF (FTXH), SPDR S&P Biotech ETF (XBI), WisdomTree BioRevolution Fund (WDNA), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC). What guidance has Blueprint Medicines issued on next quarter's earnings? Blueprint Medicines issued an update on its FY 2022 earnings guidance on Thursday, January, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $200.00 million-$200.00 million, compared to the consensus revenue estimate of $199.69 million. What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR). When did Blueprint Medicines IPO? (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. What is Blueprint Medicines' stock symbol? Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC." How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Blueprint Medicines' stock price today? One share of BPMC stock can currently be purchased for approximately $44.99. How much money does Blueprint Medicines make? Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $2.70 billion and generates $204.04 million in revenue each year. The biotechnology company earns $-557,520,000.00 in net income (profit) each year or ($9.35) on an earnings per share basis. How many employees does Blueprint Medicines have? The company employs 495 workers across the globe. How can I contact Blueprint Medicines? Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com. This page (NASDAQ:BPMC) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.